Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview
Haleh Rezaee, Fariba Pourkarim, Samira Pourtaghi‐Anvarian, Taher Entezari‐Maleki, Touraj Asvadi‐Kermani, Masoud Nouri‐Vaskeh
Abstract
Drug-drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID-19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT-prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID-19 in order to minimize the adverse reactions.
Topics & Concepts
MedicineDrugTocilizumabRitonavirCoronavirus disease 2019 (COVID-19)Adverse effectLopinavirDrug repositioningPharmacologyRibavirinDrug reactionChloroquineDrug interactionIntensive care medicineDiseaseInternal medicineVirologyInfectious disease (medical specialty)ImmunologyVirusViral loadMalariaHepatitis C virusAntiretroviral therapyCOVID-19 Clinical Research StudiesDrug-Induced Ocular ToxicitySARS-CoV-2 and COVID-19 Research